A groundbreaking clinical study reveals how targeting a rare ADAR1 gene mutation with specific inhibitors can successfully treat refractory psoriasis, offering hope for patients resistant to standard therapies.
A groundbreaking clinical study reveals how targeting a rare ADAR1 gene mutation with specific inhibitors can successfully treat refractory psoriasis, offering hope for patients resistant to standard therapies.
